CA
NZ
UK
AU
IND
US
…
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -46.59M | -62.04M | -21.81M | -75.10M | -38.71M |
| Net income | -46.21M | -61.93M | -21.63M | -74.21M | -81.15M |
| Selling general administrative | 17.25M | 24.41M | 10.53M | 17.22M | 19.26M |
| Selling and marketing expenses | 14.09M | 9.16M | 4.69M | 4.85M | - |
| Gross profit | 6.80M | 8.35M | 6.26M | 9.30M | 0.44M |
| Reconciled depreciation | 2.15M | 1.97M | 1.67M | 1.71M | 0.44M |
| Ebit | -27.08M | -29.72M | -14.12M | -15.89M | -24.55M |
| Ebitda | -24.91M | -27.75M | -12.46M | -17.22M | -24.11M |
| Depreciation and amortization | 2.16M | 1.97M | 1.67M | -1.34M | 0.44M |
| Non operating income net other | - | - | -7.30M | -1.16M | -0.16M |
| Operating income | -27.08M | -27.75M | -12.46M | -15.89M | -38.55M |
| Other operating expenses | 38.32M | 41.35M | 23.76M | 30.98M | 25.15M |
| Interest expense | 0.11M | 0.83M | 2.05M | 0.45M | 0.01M |
| Tax provision | -0.38M | -0.11M | -0.18M | -0.89M | -3.45M |
| Net interest income | -0.11M | -0.83M | -2.05M | -0.45M | -0.01M |
| Non recurring | - | - | - | 8.09M | 14.00M |
| Income tax expense | -0.38M | -0.11M | -0.18M | -0.89M | -3.45M |
| Total revenue | 11.24M | 13.60M | 11.30M | 15.09M | 0.61M |
| Total operating expenses | 33.88M | 36.10M | 18.72M | 25.19M | 24.98M |
| Cost of revenue | 4.44M | 5.25M | 5.04M | 5.78M | 0.16M |
| Total other income expense net | -19.52M | -34.29M | -9.35M | -59.21M | -14.16M |
| Discontinued operations | - | - | - | - | -45.88M |
| Net income from continuing ops | -46.21M | -61.93M | -21.63M | -74.21M | -35.27M |
| Net income applicable to common shares | -46.21M | -61.93M | -21.63M | -74.21M | -84.23M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 10.73M | 11.14M | 54.26M | 37.06M | 39.66M |
| Intangible assets | - | 0.26M | 20.83M | 27.02M | 28.67M |
| Other current assets | 0.34M | 0.08M | 1.62M | 1.07M | 1.71M |
| Total liab | 4.06M | 7.48M | 8.19M | 22.57M | 15.55M |
| Total stockholder equity | 6.66M | 3.66M | 46.07M | 14.49M | 24.11M |
| Deferred long term liab | - | - | - | 0.61M | 0.70M |
| Other current liab | 1.34M | 4.87M | 3.04M | 7.24M | 5.63M |
| Common stock | 0.02M | 0.00M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.00M | 0.02M | 0.01M | 0.00M |
| Retained earnings | -635.57M | -624.19M | -576.76M | -514.83M | -493.20M |
| Other liab | - | - | 0.85M | 1.64M | 4.68M |
| Other assets | - | 0.10M | 1.46M | 0.05M | 0.10M |
| Cash | 4.56M | 3.85M | 22.77M | 2.96M | 2.94M |
| Total current liabilities | 3.78M | 7.48M | 7.33M | 11.61M | 10.39M |
| Current deferred revenue | 0.64M | 0.51M | 0.55M | 0.40M | 0.20M |
| Net debt | -4.30M | -3.68M | -22.49M | -2.48M | -2.17M |
| Short term debt | 0.11M | 0.17M | 0.28M | 0.31M | 0.29M |
| Short long term debt total | 0.26M | 0.17M | 0.28M | 0.48M | 0.77M |
| Other stockholder equity | 642.30M | 627.93M | 622.91M | 529.43M | 517.30M |
| Property plant equipment | - | 0.87M | 1.72M | 0.58M | 0.02M |
| Total current assets | 10.30M | 9.91M | 30.25M | 8.94M | 10.11M |
| Net tangible assets | - | 3.40M | 25.25M | -12.54M | -4.57M |
| Net receivables | 1.66M | 2.18M | 2.81M | 2.62M | 4.10M |
| Long term debt | - | - | - | 9.17M | 2.73M |
| Inventory | 3.74M | 3.61M | 3.00M | 2.24M | 1.32M |
| Accounts payable | 1.69M | 1.93M | 3.47M | 3.65M | 4.26M |
| Accumulated other comprehensive income | -0.09M | -0.09M | -0.09M | -0.12M | -0.01M |
| Common stock total equity | - | - | - | 0.01M | - |
| Preferred stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -514.83M | -493.20M |
| Non currrent assets other | 0.03M | 0.05M | 1.46M | 0.05M | 0.10M |
| Non current assets total | 0.43M | 1.23M | 24.00M | 28.12M | 29.55M |
| Capital lease obligations | 0.26M | 0.17M | 0.28M | 0.48M | 0.77M |
| Long term debt total | - | - | - | 9.17M | 2.73M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -0.09M | -0.09M | 1.85M | -2.39M | -2.01M |
| Change to liabilities | - | 0.45M | -1.48M | -0.99M | 1.63M |
| Total cashflows from investing activities | - | -0.09M | 1.85M | -2.39M | -2.01M |
| Net borrowings | - | - | -9.50M | 10.40M | -0.22M |
| Total cash from financing activities | 17.57M | 3.13M | 33.30M | 11.07M | 13.66M |
| Change to operating activities | - | 0.77M | -0.61M | 0.96M | 0.89M |
| Net income | -11.39M | -46.21M | -61.93M | -21.63M | -74.21M |
| Change in cash | 0.60M | -18.86M | 19.81M | 0.02M | -2.56M |
| Begin period cash flow | 3.96M | 22.82M | 3.01M | 2.98M | 5.55M |
| End period cash flow | 4.56M | 3.96M | 22.82M | 3.01M | 2.98M |
| Total cash from operating activities | -16.96M | -21.90M | -15.38M | -8.55M | -14.20M |
| Issuance of capital stock | - | 0.64M | 0.00M | -14.61M | 0.48M |
| Depreciation | 0.15M | 2.15M | 1.97M | 1.67M | 1.71M |
| Other cashflows from investing activities | - | - | - | -2.00M | -2.00M |
| Change to inventory | -0.47M | -1.19M | -0.37M | -1.18M | -0.33M |
| Change to account receivables | 0.12M | 0.68M | -0.28M | 0.28M | 0.58M |
| Sale purchase of stock | - | - | - | 0.68M | 13.40M |
| Other cashflows from financing activities | 17.57M | 2.49M | 40.99M | 20.79M | 13.66M |
| Change to netincome | - | 21.45M | 46.83M | 9.46M | 57.84M |
| Capital expenditures | 0.04M | 0.13M | 0.35M | 0.39M | 0.01M |
| Change receivables | - | - | - | 1.22M | -3.62M |
| Cash flows other operating | - | - | - | 1.20M | 2.34M |
| Cash and cash equivalents changes | - | - | - | 0.14M | -2.56M |
| Change in working capital | -4.13M | 0.71M | -2.74M | 0.01M | -1.43M |
| Stock based compensation | 0.77M | 2.09M | 12.23M | 1.32M | 2.31M |
| Other non cash items | -2.39M | 19.79M | 34.64M | 10.17M | 58.56M |
| Free cash flow | -17.00M | -22.03M | -15.73M | -8.94M | -14.21M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
1001 Calle Amanecer, San Clemente, CA, United States, 92673
949 429 6680
29
| Name | Title | Year Born |
|---|---|---|
| Mr. Dan W. Gladney | Exec. Chair | 1953 |
| Mr. Thomas Stankovich | Sr. VP of Fin. & CFO | 1961 |
| Mr. Paul F. Hickey | CEO, Pres & Director | 1965 |
| Dr. Mark B. Knudson Ph.D. | Co-Founder and Special Advisor to the CEO | 1949 |
| Dr. Katherine S. Tweden Ph.D. | Co-Founder | 1961 |
| Mr. Al Diaz | VP of Operations and R&D | NA |
| Dr. Dov Gal D.V.M., DVM, M.B.A., MBA | VP of Regulatory Clinical Quality & Compliance Officer | NA |
| Jody B. Dahlman | Director of Communications | NA |
| Mr. Naqeeb A. Ansari | Sr. VP of Global Commercial Operations | 1961 |
| Mr. Dan W. Gladney | Executive Chair | 1953 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...